Nizaracianine triflutate

N/A

Report date: 2024/11/27 10:27:01

Base Information

Drug NameNizaracianine triflutate
Drug Alias Name9FB8TLK3DLUNII-9FB8TLK3DL2412139-24-1(2Z)-2-[(2E)-2-[2-[4-(2-carboxyethyl)phenoxy]-3-[(E)-2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]indol-1-ium-2-yl]ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethyl-1-[3-(trimethylazaniumyl)propyl]indole-5-sulfonate;2,2,2-trifluoroacetate3H-Indolium, 2-[2-[2-[4-(2-carboxyethyl)phenoxy]-3-[2-[1,3-dihydro-3,3-dimethyl-5-sulfo-1-[3-(trimethylammonio)propyl]-2H-indol-2-ylidene]ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-5-sulfo-1-[3-(trimethylammonio)propyl]-, bis(inner salt), 2,2,2-trifluoroacetate (1:1) +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsUreteral Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesLeiden University Medical CenterCuradel Surgical Innovations Inc
China Registration ClassN/A

Develop Information

Active CompaniesCuradel Surgical Innovations IncLeiden University Medical Center
Inactive CompaniesN/A
Active IndicationsUreteral Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A